Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (Form: DEFA14A, Received: 04/28/2017 16:10:25)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant  ☒                             Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under §240.14a-12

ULTRAGENYX PHARMACEUTICAL INC.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing Party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 22, 2017.

 

 

  ULTRAGENYX PHARMACEUTICAL INC.
     LOGO
 

  ULTRAGENYX PHARMACEUTICAL INC.

  60 LEVERONI COURT

  NOVATO, CA 94949

 
 
 
 
 
 
 
LOGO  

 

Meeting Information

 
Meeting Type:           Annual Meeting
For holders as of:      April 24, 2017
Date:    June 22, 2017       Time:    4:00 p.m., Pacific Time
Location:    Meeting live via the Internet-please visit
                     www.virtualshareholdermeeting.com/RARE17

 

The company will be hosting the meeting live via the Internet this year. To attend the meeting via the Internet please visit www.virtualshareholdermeeting.com/RARE17 and be sure to have the information that is printed in the box marked by the arrow LOGO (located on the following page).

 

 

You are receiving this communication because you hold shares in the company named above.
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

See the reverse side of this notice to obtain proxy materials and voting instructions.

 


— Before You Vote —

How to Access the Proxy Materials

 

          

 

Proxy Materials Available to VIEW or RECEIVE:

 

 

NOTICE AND PROXY STATEMENT    ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2016

 

How to View Online:

 

Have the information that is printed in the box marked by the arrow LOGO (located on the following page) and visit: www.proxyvote.com.

 

How to Request and Receive a PAPER or E-MAIL Copy:

 

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

 

1) BY INTERNET :        www.proxyvote.com

2) BY TELEPHONE :      1-800-579-1639

3) BY E-MAIL* :            sendmaterial@proxyvote.com

 

*  If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow LOGO (located on the following page) in the subject line.

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 8, 2017 to facilitate timely delivery.

 

 

 

— How To Vote —

Please Choose One of the Following Voting Methods

 

LOGO       

 

 

 

Vote By Internet:

 

 

Before The Meeting:

 

Go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow LOGO (located on the following page) available and follow the instructions.

 

 

During The Meeting:

 

Go to www.virtualshareholdermeeting.com/RARE17. Have the information that is printed in the box marked by the arrow LOGO (located on the following page) available and follow the instructions.

 

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 


            Voting Items                  
 

 

Company Proposals

 

The Board of Directors recommends that you vote FOR the election of the two nominees for director named below:

 

Nominees:

 

1a.    Emil D. Kakkis, M.D., Ph.D.

 

1b.    Daniel G. Welch

  
 

 

The Board of Directors recommends you vote FOR proposals 2 and 3:

 

2.      Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year  ending December 31, 2017.

 

3.      Advisory (non-binding) vote to approve the compensation of our named executive officers.

 

 

LOGO

    


 

    
    

 

 

LOGO